Illumina has appointed Agilent Technologies executive Jacob Thaysen as its new chief executive, following the departure of former CEO Francis deSouza in June and chairman
Sanofi has made an interesting choice for its new head of R&D, turning to Houman Ashrafian, who has deep expertise in the biopharma industry, but can also draw on his
Sage Therapeutics has said it will cut its headcount by 40% in the wake of the narrower-than-hoped approval of its flagship antidepressant Zurzuvae by the FDA, with two of
Mirati Therapeutics chief executive David Meek has agreed to step down by mutual agreement with the company's board, to be replaced on a temporary basis by founder and for
After months of deliberations, the National Institute of Allergy and Infectious Diseases (NIAID) has a new director to replace Dr Anthony Fauci, who held the role for 38 y
AstraZeneca's rare diseases unit Alexion has agreed to pay $1 billion to acquire Pfizer's early-stage gene therapy pipeline and enabling technologies - the company's first